Scope
The WGO 2015 global IBD guideline provides a resource-sensitive framework for distinguishing ulcerative colitis, Crohn’s disease and infectious mimics, including intestinal tuberculosis. This summary focuses on diagnostic reasoning, coordinated care and selected treatment principles. It retains the document’s historical date: the drug sequence and available advanced therapies reflect that edition, rather than a newly updated treatment hierarchy.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish the syndrome and its consequences
- Assess symptoms, prior episodes, nocturnal disturbance, weight loss and impact on usual activity. Ask about extraintestinal symptoms, perianal disease, infections, travel, medicines, smoking, family history and tuberculosis exposure. [1]
- Examine general and nutritional status, the abdomen, perianal region and extraintestinal sites. Perianal inspection should include fissures, fistulas and abscesses, with rectal assessment for strictures or a mass. [1]
- Investigate infectious diarrhoea before attributing symptoms to IBD. Include stool cultures and appropriate parasite or viral testing; consider C. difficile even without prior antibiotics, and reassess pathogens when diarrhoea flares. [1]
- Check blood count, inflammatory markers, albumin, electrolytes and relevant nutritional indices. Interpret ferritin cautiously because active inflammation may mask iron deficiency; transferrin saturation can help assess anaemia. [1]
Use endoscopy, histology and selective imaging
- Confirm and map disease through endoscopy and biopsy rather than symptoms or serology alone. Obtain biopsies from colon and terminal ileum; in severe or fulminant colitis limit the examination when needed because perforation risk is greater. [1]
- Ask histopathology specific questions: chronic architectural changes support chronic colitis, while large or caseating granulomas raise concern for tuberculosis. In immunosuppressed or steroid-treated patients with poor response, consider tissue assessment for cytomegalovirus. [1]
- Do not use p-ANCA or ASCA as routine screening substitutes for definitive investigation. ASCA cannot reliably distinguish small-bowel Crohn’s disease from intestinal tuberculosis in settings where TB is a relevant differential. [1]
- Use cross-sectional imaging to define disease extent and penetrating Crohn’s complications. Prefer ultrasound or MRI where appropriate to reduce repeated radiation exposure; pelvic MRI is the reference investigation for perianal Crohn’s fistulas in this guideline. [1]
- Capsule endoscopy can help when suspected small-bowel Crohn’s disease remains unclear after initial investigation. Evaluate possible stenosis first; a patency capsule may be used when narrowing is known or uncertain. [1]
Apply the resource and infection context
- Adapt the diagnostic work-up to available resources while retaining clinical assessment, stool infection testing, blood count and albumin. Add ileocolonoscopy with biopsy when available. [1]
- Where intestinal TB is prevalent, the guideline calls for TB PCR and culture during lower endoscopy. Interpret immune-based TB tests carefully during immunosuppression, and use the clinical, endoscopic and radiological picture together. [1]
Set goals and support the patient
- Base treatment on disease type, location and phenotype, severity, complications, response, tolerability and access. Coordinate physicians and surgeons when surgery may be needed, rather than treating medical and surgical options as unrelated decisions. [1]
- Aim for symptom and inflammation control, good nutrition and corticosteroid-free remission, while limiting treatment harm and preventing hospitalisation or surgery. Include the patient’s view of quality of life in the treatment goal. [1]
- Support smoking cessation, particularly in Crohn’s disease, and attend to psychological comorbidity and stress. Nutritional supplementation is appropriate with malnutrition or reduced intake; replenish vitamin B12 when deficient. [1]
Selected treatment and complication principles
- For ulcerative colitis, the guideline describes oral and rectal 5-ASA for maintenance and combined oral/topical treatment for active mild-to-moderate disease. Its Crohn’s recommendations are distinct and should not be inferred from the ulcerative-colitis pathway. [1]
- Corticosteroids are induction treatment, not maintenance therapy. Long-term use is limited by adverse effects; the guideline advises calcium and vitamin D alongside monitoring of blood pressure and glucose during corticosteroid treatment. [1]
- Seek C. difficile and CMV in refractory colitis. For acute severe ulcerative colitis failing intravenous steroids, consider colectomy in a timely way rather than allowing prolonged ineffective treatment. [1]
- For perianal Crohn’s disease with an abscess, surgical management is required; the resource cascades favour combined medical and surgical care. Selected short, straight, accessible strictures may be dilated only with surgical support available for failure or complications. [1]
Limitations and use
- This is the 2015 WGO document. Use newer disease-specific guidance for contemporary drug selection, biologic sequencing, cancer surveillance and perioperative therapy; this summary does not silently modernise the old recommendations.
- Detailed diagnostic and disease-status tables, medication doses, empiric TB treatment and complete acute-severe-colitis rescue pathways are outside this summary.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Inflammatory bowel disease: WGO global guideline
Selected recommendation material consulted
Publication details
- Issuing organisation
- World Gastroenterology Organisation
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: inflammatory bowel disease acg
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.